Health Bulletin 02/ April/ 2024

Here are the top health stories for the day:

CDSCO issues alert for 58 drug samples

In its latest drug safety alert, the apex drug regulatory body, the Central Standard Control Organisation (CDSCO) has flagged 58 medicine batches for failing to qualify for a random sample test for February 2023, while 2 drug samples have been declared as suprious.

These drugs include Acepik – P (Aceclofenac and Paracetamol Tablets) manufactured by Nexkem Biotech, Amoxycillin Oral Suspension I.P. (Medmoxil 125) manufactured by Laborate Pharmaceuticals, Calcium Carbonate and Vitamin D3 Tablets IP (Calcigiant 500 Tablets) manufactured by Nutra Life Healthcare, Ofloxacin manufactured by Concept Pharmaceutical, Calcium and Vitamin D3 Tablets manufactured by Hanuchem Laboratories, Serratiopeptidase Tablets manufactured by Arnav Research Laboratories.

For more information, click on the link below:

CDSCO Drug Alert: 58 Drug Samples Including Alkems’s Pyricool 500, Glenmark’s Deferasirox, Sun Pharma’s Zole F Flagged

NMC panel consensus: Corporate hospitals advert decision heads to Supreme Court

The National Medical Commission’s (NMC) panel, which was formed based on the Supreme Court’s directions to examine the issue of advertising by corporate hospitals, is going to submit its recommendations to the Supreme Court.

Reaching a consensus, the NMC panel has opined that the rules of advertisement shall be the same for the corporate hospitals as well as for the doctors and other health facilities, The Print has reported.

For more information click on the link below:

WHO publishes new guidelines on hepatitis B
In a landmark move, the World Health Organization (WHO) has released groundbreaking guidelines to address the global challenge of chronic hepatitis B (HBV) infection. Unveiled at the 2024 Asian Pacific Conference for the Study of Liver Disease in Kyoto, Japan, these guidelines aim to simplify and expand access to HBV testing and treatment, marking a crucial step towards the WHO’s goal of eliminating viral hepatitis by 2030. With over 250 million people worldwide living with HBV, the new WHO guidelines focus on preventing mother-to-child transmission, a key transmission route, by recommending antiviral treatment for pregnant women and immediate newborn vaccination. This approach not only aims to reduce the global burden of HBV but also prevents liver-related complications, aligning with India’s efforts to curb the disease through its Universal Immunization Program (UIP).
Additionally, they focus on improving HBV diagnostics, addressing hepatitis delta coinfection, and enhancing the delivery of HBV services to ensure long-term adherence to therapy and retention in care.


Almost 50,000 excess deaths estimated globally due to disrupted routine vaccinations: Study

A new modeling study published in The Lancet Global Health journal estimated the health effects of COVID-19-related immunization disruptions in 112 countries during 2020–30.

The researchers used modeling groups from the Vaccine Impact Modelling Consortium from 112 low- and middle-income countries to estimate vaccine effects for 14 disease-causing pathogens. They revealed close to 50,000 additional deaths globally are estimated between 2020 and 2030 due to pandemic-related disruptions to immunization.
For more information, click on the link below:
COVID-19-Related Immunization Disruptions Tied To About 50000 Excess Deaths Globally: Lancet
Facebook Comments